GlassScriptPhysician profile
Kasey Weaver
NPI 1306403449
$1,708.58
in general payments reported to CMS, 2019-2025
16 companies · $1,375 in 2025
The $1,375 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $152 · 2022: $152 · 2023: $29.75 · 2025: $1,375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,404.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $257.38 | 2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $170.90 | 2025 | Zoryve |
| Organon LLC | $161.06 | 2025 | Vtama |
| Allergan, INC. | $152.46 | 2022 | |
| Novo Nordisk INC | $151.61 | 2021 | |
| Pfizer INC. | $151.25 | 2025 | |
| Ucb, INC. | $142.90 | 2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $121.03 | 2025 | Dupixent |
| Genzyme Corporation | $92.47 | 2025 | |
| Amgen INC. | $72.56 | 2025 | Otezla |
| Abbvie INC. | $62.18 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $52.18 | 2025 | |
| Lilly USA, LLC | $46.84 | 2025 | Ebglyss |
| Sun Pharmaceutical Industries INC. | $35.05 | 2025 | |
| Incyte Corporation | $23.89 | 2025 | Opzelura |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $14.82 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kasey Weaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.